Clinical Trials Directory

Trials / Recruiting

RecruitingNCT04794686

ETMR One: An International Registry and Research Platform for Children With Embryonal Tumor With Multilayer Rosettes

Status
Recruiting
Phase
Study type
Observational
Enrollment
100 (estimated)
Sponsor
Hackensack Meridian Health · Academic / Other
Sex
All
Age
Healthy volunteers

Summary

This research is being done to find out more information about a brain tumor called Embryonal Tumor with Multilayer Rosettes (ETMR) by collecting medical information from children who have this disease. The purpose of this research study is to create and maintain a research database for patients with ETMR. The database will include information about occurrence rates, patient information, tumor tissue information, and response to treatment. This will help advance our understanding of this rare disease. In addition, this study will include obtaining survival data and evaluating therapeutic response to expert consensus therapy, and procuring patient tumor tissue.

Detailed description

All patients with ETMR are eligible for inclusion within the registry, regardless of their disease status or treatment plan. Epidemiologic, clinical, and molecular data from each patient will be obtained following enrollment. Patients will then be followed longitudinally to obtain clinical outcome data. In an effort to best achieve the registry's secondary objectives, it is preferable, but not required, for patients to be registered soon after their diagnosis, prior to the initiation of any tumor-directed therapy. This registry protocol contains recommendations for a consensus therapy derived from the ETMR medical literature, the investigators' own experience, and clinical data from other infant brain tumor protocols. The recommended therapy can thus not be viewed as investigational, but rather as a consensus recommendation derived from available data. While not mandated, it is strongly encouraged that patients enrolled in the registry be treated according to the recommended consensus therapy, as this will facilitate the prospective evaluation of ETMR patients using a uniform treatment approach.

Conditions

Timeline

Start date
2020-07-12
Primary completion
2030-07-12
Completion
2030-07-12
First posted
2021-03-12
Last updated
2025-06-04

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT04794686. Inclusion in this directory is not an endorsement.